Antimetastatic effect of tinzaparin, a low-molecular-weight heparin.
about
Systemic coagulation parameters in mice after treatment with vascular targeting agents.The effect of low molecular weight heparin on survival in cancer patients: an updated systematic review and meta-analysis of randomized trialsEffect of non-anticoagulant N-desulfated heparin on expression of vascular endothelial growth factor, angiogenesis and metastasis of orthotopic implantation of human gastric carcinoma.Anti-metastatic effect of a non-anticoagulant low-molecular-weight heparin versus the standard low-molecular-weight heparin, enoxaparinImpact of venous thromboembolism and anticoagulation on cancer and cancer survivalPretreatment platelet count as a predictor for survival and distant metastasis in nasopharyngeal carcinoma patients.Tissue factor, blood coagulation, and beyond: an overview.Venous thromboembolism and malignancy.Low-molecular-weight heparins and angiogenesis.Anti-thrombotics in thrombosis and cancer.Identification of a novel platelet antagonist that binds to CLEC-2 and suppresses podoplanin-induced platelet aggregation and cancer metastasisThe antineoplastic effect of low-molecular-weight heparins - a literature reviewHeparins attenuate cancer metastasis: are selectins the link?Heparins that block VEGF-A-mediated von Willebrand factor fiber generation are potent inhibitors of hematogenous but not lymphatic metastasis.Low-molecular-weight heparins and cancer: focus on antitumoral effect.Extracellular vesicles from malignant effusions induce tumor cell migration: inhibitory effect of LMWH tinzaparin.Experimental metastasis and primary tumor growth in mice with hemophilia A.Effect of MCM09, an active site-directed inhibitor of factor Xa, on B16-BL6 melanoma lung colonies in mice.D-dimers in malignant melanoma: Association with prognosis and dynamic variation in disease progress.Dalteparin, a low-molecular-weight heparin, promotes angiogenesis mediated by heparin-binding VEGF-A in vivo.In Surgical Colon Cancer Patients Extended-Duration Thromboprophylaxis (30 days) with the Highest Dose of Tinzaparin (4,500 IU s.c./q.d.) Normalizes the Postoperative VEGF Levels.Transglutaminase activity in acute infarcts predicts healing outcome and left ventricular remodelling: implications for FXIII therapy and antithrombin use in myocardial infarction.The Impact of Vascular Disease Treatment on Platelet-Derived Microvesicles.Comparative pharmacodynamic assessment of the antiangiogenesis activity of heparin and low-molecular-weight heparin fractions: structure-function relationship.Platelet count as a predictor of metastasis and venous thromboembolism in patients with cancer.The Role of Tinzaparin in Oncology.
P2860
Q25257132-A567FAC1-AB3D-4F8B-8658-DC9318E12B4FQ26852293-85C5FC68-6275-44BE-999E-150238A766C5Q33269554-06773DF0-58BB-4E24-906A-A0C41770AA39Q33373462-91158DF2-62A6-4715-B871-CE74281FD907Q33561203-4FDCE5E4-911D-407F-9E0B-2752FE7D347AQ35042007-3E072B83-0A19-4990-AB31-0680B1AD345AQ35222618-324F370A-D833-46CF-B18A-4AD9054565C5Q35728779-EBBF073A-A46F-409A-9C25-E65835779297Q36414904-D59BE49B-52E1-42B0-8357-B52F173D9DFDQ36429503-7C5FDD8E-5A8E-4043-9C3F-824E3A6F8D04Q36618989-219FF390-23DB-40C5-87EA-5D218890D6ACQ36936771-1F5F45E0-240D-4664-AE22-FE3D2B3AC74AQ37500092-3E0FD3C1-E569-46AD-BE68-CDD21A4EC847Q37708829-B071B2BF-1816-4A9A-BA0F-F2B2EE37C40BQ38376242-3ECAD38F-C8A3-4309-BC02-A8A78120492FQ38756901-9BA92AA3-B842-44E2-83B0-31408A25940FQ40281264-3B63CC5A-D5F5-47CE-B456-639192231766Q40320314-EA2F444F-87B7-4E8E-8BF3-D17E64AFE7B4Q40489634-90F97511-E601-4225-92CE-8D4AB46BFF9EQ41212817-FE3CE988-2D8A-4FF0-A0FD-04EAFEBD855EQ41721711-5C2C583E-2890-4D0A-8D6A-525C33FFC501Q46752654-FD9C01FA-A997-446B-81A7-EC20EF56D949Q47159100-A1FA9159-E71E-437F-912E-82EBA952D388Q47326919-30BA56A7-6F37-4036-B620-4747DBC5044EQ47400340-465DDF9B-35C0-471D-B654-F54D74E92581Q47681124-A30B05EC-5BDE-4F63-9ABF-2B57F4B55FE5
P2860
Antimetastatic effect of tinzaparin, a low-molecular-weight heparin.
description
2003 nî lūn-bûn
@nan
2003 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Antimetastatic effect of tinzaparin, a low-molecular-weight heparin.
@ast
Antimetastatic effect of tinzaparin, a low-molecular-weight heparin.
@en
type
label
Antimetastatic effect of tinzaparin, a low-molecular-weight heparin.
@ast
Antimetastatic effect of tinzaparin, a low-molecular-weight heparin.
@en
prefLabel
Antimetastatic effect of tinzaparin, a low-molecular-weight heparin.
@ast
Antimetastatic effect of tinzaparin, a low-molecular-weight heparin.
@en
P2093
P2860
P1476
Antimetastatic effect of tinzaparin, a low-molecular-weight heparin.
@en
P2093
A Amirkhosravi
J L Francis
P2860
P304
P356
10.1046/J.1538-7836.2003.00341.X
P577
2003-09-01T00:00:00Z